RxDoctor Payments Data

Michael Zdunich, PA

Medical · Conway, SCNPI 1750999660

Payments from drug & device makers

$1,068in general payments, 2019–2025

Across 43 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$370
  • Sumitomo Pharma America, Inc.$233
  • Endo Pharmaceuticals Inc.$78
  • Bayer$43
  • Takeda Pharmaceuticals U.S.A., Inc.$42
  • Blue Earth Diagnostics$38
  • plus $264 from 13 others

What the payments were for

  • Food & beverage$1,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,068 in reported general payments places this provider in the 50th percentile of 384 medical providers in South Carolina.

See all medical providers in South Carolina

Medicare billing

Part B allowed, 2024
$347,908
Medicare patients
830
Services billed
113,998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron45$32,710
GemtesaVibegron16$11,212
Mirabegron ErMirabegron20$8,267
Tamsulosin Hcl249$4,728
Testosterone Cypionate107$3,168
Finasteride140$2,701
Solifenacin Succinate56$2,449
Potassium Citrate ErPotassium Citrate45$2,234
Estradiol25$1,801
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst84$1,582
Anastrozole179$887
Doxycycline Monohydrate81$854
Bethanechol Chloride11$453
Ciprofloxacin Hcl24$139
Nystatin11$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$233$11,21216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 384 medical providers in South Carolina.

Other medical in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →